hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06301906 id: 202301060A3 briefTitle: Red Yeast Rice for Primary Prevention of Hypercholesterolemia overallStatus: RECRUITING date: 2024-02-26 date: 2025-12-31 date: 2025-12-31 date: 2024-03-08 date: 2024-03-08 name: Chang Gung Memorial Hospital class: OTHER briefSummary: This two-year observational study will be conducted at the outpatient clinic of the Department of Traditional Chinese Medicine of Taoyuan Chang Gung Hospital from February 26, 2024 to December 31, 2025. This study will enroll 35\~55 year-old male patients who are expected to take LipoCol Forte Capsules for primary prevention of hypercholesterolemia. The investigators will collect the TCM constitution questionnaires from patients before taking LipoCol Forte Capsules and every three months after taking the medicine. At the same time, blood will be drawn to detect glycated hemoglobin, fasting blood sugar, insulin, lipids profile, liver and kidney function, creatine kinase, predictive parameters of atherosclerotic cardiovascular disease, and plasma bile acids, etc. Fecal samples will also be collected to analyze the intestinal microbiota and fecal bile acid composition. This study will evaluate the efficacy, durability and safety of LipoCol Forte capsules in the primary prevention of hypercholesterolemia in patients with different constitutions, as well as whether it can reduce the risk of cardiovascular disease, and its influence on bile acid metabolism and intestinal microbiota. conditions: Hypercholesterolemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: LipoCol Forte Capsule 600mg bid measure: Low Density Lipoprotein-Cholesterol (LDL-C) measure: 10-Year ASCVD Risk sex: MALE minimumAge: 35 Years maximumAge: 55 Years stdAges: ADULT facility: Taoyuan branch of Chang Gung Memorial Hospital status: RECRUITING city: Taoyuan zip: 333 country: Taiwan name: Yueh Hsiang Huang, PhD role: CONTACT phone: 886-975360240 email: igighuang@gmail.com lat: 24.95233 lon: 121.20193 hasResults: False
nctId: NCT06301893 id: US-3_Uganda (IRB#2013-4576) briefTitle: Uganda Sickle Surveillance Study (US-3) overallStatus: RECRUITING date: 2013-09-07 date: 2030-12-31 date: 2032-12-31 date: 2024-03-08 date: 2024-03-12 name: Children's Hospital Medical Center, Cincinnati class: OTHER name: Makerere University name: Ministry of Health, Uganda name: Mulago Hospital, Uganda briefSummary: It is estimated that over 250,000 babies are born with sickle cell disease (SCD) annually in sub-Saharan Africa, and only 10% - 50% of them survive beyond five years of age. Data describing the magnitude of the sickle cell problem are lacking in most African countries. The available data on prevalence were mainly from older studies and small numbers of hospitalized patients. In Uganda, approximately 25,000 children are born with SCD but 70-80% die before their 5th birthday. Lehmann and Raper found 'sicklaemia' prevalence of 0.8% and 45% in the Sebei and Bambaa ethnic groups, respectively. A recent study found a SCT and SCD prevalence of 3% - 19% and 0% - 3%, respectively but this study addressed only 5 of Uganda's 111 districts and used a small convenience sample of children aged 6 - 60 months. The objective of this study is to determine the prevalence and map out the burden of SCT and SCD in Uganda. conditions: Sickle Cell Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 1000000 type: ESTIMATED measure: Incidence of HbSS and HbA measure: Incidence of HbSS and HbA sex: ALL maximumAge: 12 Months stdAges: CHILD facility: Makerere University status: RECRUITING city: Kampala country: Uganda name: Grace Ndeezi, MBChB, MMed, PhD role: CONTACT lat: 0.31628 lon: 32.58219 facility: Minister of Health status: RECRUITING city: Kampala country: Uganda name: Jane R. Aceng, MD role: CONTACT lat: 0.31628 lon: 32.58219 facility: National Coordinator EID Program status: RECRUITING city: Kampala country: Uganda name: Charles Kiyaga, MBLSM role: CONTACT name: Charles Kiyaga, PhD role: SUB_INVESTIGATOR lat: 0.31628 lon: 32.58219 facility: Sickle Cell Clinic Department of Pediatrics & Child Health Mulago Hospital status: RECRUITING city: Kampala country: Uganda name: Deogratias Manube, MBChB, MMed role: CONTACT lat: 0.31628 lon: 32.58219 hasResults: False
nctId: NCT06301880 id: 3200 briefTitle: Effect of Topically-applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow overallStatus: COMPLETED date: 2022-01-01 date: 2023-01-31 date: 2023-01-31 date: 2024-03-08 date: 2024-03-08 name: Damascus University class: OTHER briefSummary: Forty-six consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled. After the left IMA was harvested, free flow was measured under controlled hemodynamic conditions before any intervention (flow 1) and at a mean of 12.5 minutes after the topical application of one of three agents (milrinone, nitroglycerin or normal saline) on the IMA (flow 2). conditions: Internal Mammary Artery Syndrome conditions: Vasodilation studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: All surgical procedures and measurements were carried out by a single surgeon (MBI) who was blinded to the topical agent which was applied. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 46 type: ACTUAL name: The topical application of a vasodilator on the LIMA graft measure: LIMA free flow sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Damascus University Cardiac Surgery Hospital city: Damascus country: Syrian Arab Republic lat: 33.5102 lon: 36.29128 hasResults: False
nctId: NCT06301867 id: Pro00113877 briefTitle: Preventing Failed Extubations acronym: PreFIX overallStatus: RECRUITING date: 2024-03-01 date: 2024-07-31 date: 2024-08-31 date: 2024-03-08 date: 2024-03-21 name: Duke University class: OTHER briefSummary: More than 300,00 people in the United States experience acute respiratory failure and require mechanical ventilation every year. Of those that recover and are extubated, the most common reason for reintubation is recurrent respiratory failure. Our study proposes a novel methodology for identifying those patients most at risk for recurrent respiratory failure. conditions: Mechanical Ventilation Complication conditions: Weaning Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 250 type: ESTIMATED name: Plateau Pressure measure: Percentage of patients who had a plateau pressure measured prior to extubation as a measure of feasibility measure: Percentage of patients who were reintubated prior to hospital discharge sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Duke University Medical Center status: RECRUITING city: Durham state: North Carolina zip: 27710 country: United States name: Elias H Pratt, MD role: CONTACT email: elias.pratt@duke.edu lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06301841 id: 2023-A00903-42 briefTitle: An Antibiotic Protocol Guided by a Multimodal Approach in AECOPD With Pneumonia in Intensive Care acronym: BPCTréa2 overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-04-15 date: 2026-07-15 date: 2024-03-08 date: 2024-03-08 name: University Hospital, Caen class: OTHER briefSummary: Investigators propose to conduct a multicenter, prospective, randomized, controlled, assessing the interests of an antibiotic protocol guided by the combined use of serum procalcitonin (PCT) and a broad-panel respiratory multiplex PCR (mPCR) to reduce duration of antibiotics exposure in patients with chronic obstructive pulmonary disease (COPD) hospitalized in intensive care unit (ICU) with pneumonia. The primary endpoint is the number of antibiotic-days for the treatment of pneumonia. conditions: To Reduce Duration of Antibiotics Exposure in Patients With COPD Hospitalized in Intensive Care Unit With Pneumonia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: experimental measure: Duration of antibiotic therapy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical Intensive Care Unit, CHU Caen city: Caen zip: 14000 country: France lat: 49.18585 lon: -0.35912 hasResults: False
nctId: NCT06301828 id: KY202401 briefTitle: Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors overallStatus: RECRUITING date: 2024-02-21 date: 2025-06-21 date: 2026-02-21 date: 2024-03-08 date: 2024-03-08 name: Nanjing First Hospital, Nanjing Medical University class: OTHER briefSummary: This is a single-arm, prospective, exploratory clinical study to evaluate the efficacy and safety of endostar combined with stereotactic body radiation therapy (SBRT) and Envafolimab in patients with advanced gastrointestinal cancer after multi-line treatment. conditions: Gastrointestinal Neoplasms studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Gastrointestinal neoplasms primaryPurpose: TREATMENT masking: NONE count: 16 type: ESTIMATED name: Envafolimab Injection name: Endostar measure: DCR measure: ORR measure: PFS measure: Incidence of Treatment-Emergent Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanjing First Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210006 country: China name: wei x wei, M.D. role: CONTACT phone: 52271000 phoneExt: 025 lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06301815 id: Shaw_Stroke_REC24/YH/0010_2024 briefTitle: Feasibility of Measuring Vertical Perception in Acute Stroke overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-10-31 date: 2024-12-31 date: 2024-03-08 date: 2024-03-08 name: University of Winchester class: OTHER name: Hampshire Hospitals NHS Foundation Trust name: University Hospitals Dorset NHS Foundation Trust briefSummary: The goal of this observational study is to establish if it is feasible to identify vertical perception deficits in people with acute stroke. The primary purpose to the study is:
Participants will be asked to complete the assessments with a therapist 48 hours after admission. If they are not completed for any reason attempts will be made to complete them at one, two and four weeks after admission. Some participants will have them completed again on discharge. The Catherine Bergego Scale and SCP are observational and will involve a therapist watching the participant undertake daily activities. The bucket test involves a therapist placing a bucket in front of the face of the participant and asking them to identify when a line on the bottom of the bucket is vertical. Acceptabiliy and feasibility will be further investigated using a survey of participants who complete the assessments and through focus groups with the rehabilitation professionals admininstering the assessments.
If it is feasible and acceptable to complete these assessments then further research can use them as an acceptable measure of vertical alignment in the clinical setting. conditions: Stroke studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED name: Scale for Contraversive Pushing name: Catherine Bergego Scale name: Bucket Test measure: Bucket Test to measure subjective visual vertical (SVV). measure: Catherine Bergego Scale to measure neglect. measure: Scale for Contraversive Pushing to measure lateropulsion sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Royal Hampshire County Hospital city: Winchester zip: SO22 5DG country: United Kingdom name: Amelia Shaw, MSc role: CONTACT phone: 01962 824940 email: amelia.shaw@hhft.nhs.uk lat: 51.06513 lon: -1.3187 hasResults: False
nctId: NCT06301802 id: myelomeningocele management briefTitle: Outcomes of Proactive Management of Children With Myelomeningocele overallStatus: RECRUITING date: 2024-03-04 date: 2026-03-10 date: 2026-03-15 date: 2024-03-08 date: 2024-03-08 name: Assiut University class: OTHER briefSummary: Spina bifida birth prevalence in Africa is 0.13%. Myelomeningocele (MMC) represents the most frequent and most severe cause of NB in children. Treatment of neuropathic bladder secondary to spina bifida is an ongoing challenge. Damage of the renal parenchyma in children with NB is preventable given adequate evaluation, follow-up and proactive management. Proactive management was defined as use of clean intermittent catheterization (CIC), and/or anticholinergics at presentation, or based on initial high-risk urodynamic findings by 1 year of age. The proactive approach to treat SB (CIC and pharmacotherapy) has contributed to decreasing chronic kidney disease (CKD). Myelomeningocele is considered a complex congenital disease. Hence, a multidisciplinary team is the best choice for management of spina bifida, involving neurosurgeons, orthopedic surgeons, urologists, physical medicine and rehabilitation specialists and pediatricians. Currently, children with spina bifida in Egypt must visit multiple different locations to access the complex care they need. Here, we review our experience with patients with spina bifida who will be followed with this team with an emphasis on patients' upper urinary tract protection and decreasing urinary incontinence. conditions: Urologic Diseases studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: CIC name: Anticholinergic measure: upper tract affection sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Assiut university hospital status: RECRUITING city: Assiut zip: 11571 country: Egypt name: Islam Mahmoud, DR role: CONTACT phone: 00201090088672 email: doctorislam672@gmail.com lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06301789 id: Quadratus lumborum block briefTitle: Role of Magnesium Sulphate as an Adjuvant to Bupivacaine in U.S Guided Quadratus Lumborum Block in Lower Abdominal Cancer Surgeries overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-02 date: 2026-03 date: 2024-03-08 date: 2024-03-08 name: Assiut University class: OTHER briefSummary: The aim of this study is to assess the efficacy of Mg sulfate ( 10% ) as an adjuvant to Bupivacain ( 0.25 % ) in an U.S guided QLB for postoperative analgesia and postoperative Morphine consumption in lower abdominal cancer surgeries. conditions: QLB in Lower Abdominal Cancer Surgeries as a Post Operative Analgesia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Effect of adding Mg sulphate as an adjuvant to bupivacaine for postoperative analgesia in cases of lower abdominal cancer surgeries primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 52 type: ESTIMATED name: Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries measure: Postoperative analgesia sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06301776 id: Bridge-2023-02-0A briefTitle: A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge overallStatus: RECRUITING date: 2023-12-05 date: 2025-12-31 date: 2026-06-30 date: 2024-03-08 date: 2024-03-08 name: The Fourth Affiliated Hospital of China Medical University class: OTHER briefSummary: To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral artery stenosis in subjects who had been taking different durations of dual-antiplatelet therapy (3 vs 6 months) and ticagrelor monotherapy. conditions: Brain Disease conditions: Vertebral Artery Stenosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 560 type: ESTIMATED name: Ticagrelor measure: Incidence of the composite endpoint of non-fatal ischaemic Stroke, TIA, and all-cause mortality at 12-months. measure: Incidence of the composite endpoint of major bleeding and hemorrhagic stroke at 12-months. measure: Incidence of target vessel-related stroke and neurological death at 1month measure: Incidence of stroke and neurological death at 12 month. measure: Incidence of all-cause mortality at 12 month. measure: Incidence of in-stent-stenosis at 12 month (subgroup of imaging follow-up). sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the Fourth Affiliated Hospital of China Medical University status: RECRUITING city: Shenyang state: Liaoning zip: 110032 country: China name: Lianbo Gao role: CONTACT email: gaolbdoc@163.com lat: 41.79222 lon: 123.43278 hasResults: False
nctId: NCT06301763 id: nosencekCancer-old briefTitle: Oral Enteral Nutrition in Delayed Onset Radiotherapy-related Swallowing Disorder in Nasopharyngeal Carcinoma overallStatus: COMPLETED date: 2022-06-01 date: 2022-12-25 date: 2022-12-31 date: 2024-03-08 date: 2024-03-12 name: Muhammad class: OTHER briefSummary: This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received IOE while the control group received NGT for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (QOL) after treatment as well as adverse events are compared. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 56 type: ACTUAL name: Intermittent Oral-esophageal Tube Feeding name: nasogastric tube feeding measure: Hemoglobin Level measure: Serum albumin Level measure: Total serum protein Level measure: Serum prealbumin Level measure: Body Mass Index Level measure: Depression measure: Swallowing-Quality of Life questionnaire measure: Functional Oral Intake Scale measure: Penetration-Aspiration Scale sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ubonratchathani Hospital city: Ubon Ratchathani country: Thailand lat: 15.23844 lon: 104.84866 hasResults: False
nctId: NCT06301750 id: Tube-Alzheimer briefTitle: Oral Enteral Nutrition Feeding in Alzheimer's Patients overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-03-08 date: 2024-03-12 name: Muhammad class: OTHER briefSummary: This is a prospective multicenter study with Alzheimer's patients with dysphagia. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received Intermittent Oral-esophageal Tube Feeding while the control group received Nasogastric Tube Feeding for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment are compared. conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Conventional Care name: Intermittent Oral-esophageal Tube Feeding name: Nasogastric tube measure: Level of Hemoglobin measure: Level of Serum albumin measure: Level of Total serum protein measure: Level of Serum prealbumin measure: Body Mass Index measure: Pulmonary Infections measure: Mini Nutritional Assessment sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06301737 id: SGB-YanD briefTitle: Lidocaine Injection: A Nove Block Therapy for Stroke-related Dysphagia overallStatus: COMPLETED date: 2022-06-21 date: 2023-05-02 date: 2023-05-17 date: 2024-03-08 date: 2024-03-25 name: Muhammad class: OTHER briefSummary: This was a multicenter randomized controlled study. 66 post-stroke patients with pharyngeal dysphagia were randomly allocated to the observation group (n=33) or the control group (n=33). Both groups were provided with comprehensive rehabilitation including routine rehabilitation and swallowing function training. Besides, the observation group additionally underwent the stellate ganglion block (SGB). At admission and after 20-day treatment, Kubota water swallowing test, video fluoroscopic swallowing study (VFSS), and Rosenbek penetration-aspiration scale (PAS) were used to assess swallowing function. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 65 type: ACTUAL name: Comprehensive rehabilitation name: Injection name: Lidocaine Hydrochloride measure: Video fluoroscopic swallowing study measure: Rosenbek penetration-aspiration scale measure: Functional Oral Intake Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhen No.1 Hos. city: Taiwan country: China lat: 32.32812 lon: 118.76384 hasResults: False
nctId: NCT06301724 id: SGB-PKS briefTitle: Effectiveness of Stellate Ganglion Block in Individuals With Parkinson's Disease overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-03-08 date: 2024-03-12 name: Muhammad class: OTHER briefSummary: The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in patients with Parkinson's disease. The main question it aims to answer are:
Participants will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Injection name: Lidocaine hydrochloride measure: Penetration-Aspiration Scale measure: Modified Barthel Index measure: Functional Oral Intake Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False